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Background: Informed consent based on comprehension of potential risks and benefits is fundamental to the
ethical conduct of clinical research. We explored mental models of candidate HIV vaccines and clinical trials that
may impact on the feasibility and ethics of biomedical HIV prevention trials among men who have sex with men
(MSM) in India.
Methods: A community-based research project was designed and implemented in partnership with community-
based organizations serving MSM in Chennai and Mumbai. We conducted 12 focus groups (n = 68) with diverse
MSM and 14 key informant interviews with MSM community leaders/service providers using a semi-structured
interview guide to explore knowledge and beliefs about HIV vaccines and clinical trials. Focus groups (60–
90 minutes) and interviews (45–60 minutes) were conducted in participants’ native language (Tamil in Chennai;
Marathi or Hindi in Mumbai), audio-taped, transcribed and translated into English. We explored focus group and
interview data using thematic analysis and a constant comparative method, with a focus on mental models of HIV
vaccines and clinical trials.
Results: A mental model of HIV vaccine-induced seropositivity as “having HIV” resulted in fears of vaccine-induced
infection and HIV stigma. Some participants feared inactivated vaccines might “drink blood” and “come alive”.
Pervasive preventive misconception was based on a mental model of prevention trials as interventions,
overestimation of likely efficacy of candidate vaccines and likelihood of being assigned to the experimental group,
with expectations of protective benefits and decreased condom use. Widespread misunderstanding and lack of
acceptance of placebo and random assignment supported perceptions of clinical trials as “cheating”. Key informants
expressed concerns that volunteers from vulnerable Indian communities were being used as “experimental rats” to
benefit high-income countries.
Conclusions: Evidence-informed interventions that engage with shared mental models among potential trial
volunteers, along with policies and funding mechanisms that ensure local access to products that demonstrate
efficacy in trials, may support the safe and ethical implementation of HIV vaccine trials in India.
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It is an ethical imperative that prospective research
volunteers are to be provided adequate information
about clinical trials and their potential risks and benefits
to enable meaningful informed consent [1,2]. Providing
information alone, however, even lay descriptions of sci-
entific concepts, may be insufficient to support under-
standing and fully informed decisions about clinical
trial participation [2-4]. Challenges for achieving par-
ticipation based on meaningful informed consent may
be even greater in clinical trials sponsored by rich coun-
tries of the Global North conducted among marginal-
ized communities in the Global South; yet this is a
necessary reality if we are to develop HIV vaccines with
demonstrated efficacy in the developing world, where
they are most sorely needed [5-7].
India, with a population of 1.2 billion and the second
highest number of persons living with HIV in the world
[8], as well as expertise in vaccine production [9], is a
strategically important site for HIV vaccine research.
Nevertheless, a history of some unethical clinical trials
[9-11], challenges surrounding the implementation of
Phase I HIV vaccine trials [12-14] and ongoing contro-
versy over roll-out of licensed vaccines in India [15-22]
suggest the critical importance of formative research to
support the ethical conduct of HIV vaccine trials based
on meaningful informed consent. In particular, “social
resistance and rumours” have been documented in regard
to oral polio vaccines, founded on mistrust of vaccine
efficacy and the government’s intentions [15,16]. Con-
troversies have also erupted in response to a demonstra-
tion project that administered human papillomavirus
vaccine to 23,000 adolescent girls in two Indian states,
documented in both medical journals [17,18] and the
media [20-22]. The deaths of four girls were alleged to
be vaccine-related, with further contentions that partici-
pants did not fully comprehend the risks of vaccination
despite signing a consent form.
Further challenges may arise in conducting HIV vac-
cine trials with marginalised communities. In India,
HIV prevalence among men who have sex with men
(MSM) (7.4%) is more than 20-fold higher than the gen-
eral population (0.3%) [8]. A concentrated epidemic
among MSM makes this a potentially viable community
for HIV vaccine trials. However given that adult consen-
sual same-sex sexual behaviour was a criminal offence
in India until 2009 [23], and stigma and discrimination
against MSM is still rampant in general society and
healthcare settings [24], participating in HIV prevention
trials may engender particular concerns among MSM [3].
Mental models
Comprehension of new information is contingent on
how that information fits within pre-existing mentalmodels [25-27]. Mental models are simplified cognitive
representations of complex external realities; they may
be incomplete, but are useful in guiding reasoning,
decision-making and behaviour [25,26,28]. A mental
models approach has been applied in health and environ-
mental risk domains to support informed decision-making
and promote safer behaviours [26,28]. Mental models have
also been elicited to understand fears and misconceptions
regarding licensed vaccines and thereby to support
strategies to increase uptake [29,30]. For example, a
mental models approach indicated that even parents who
reported generally positive attitudes towards childhood
vaccination expressed lingering concerns and mis-
conceptions about the need for multiple injections,
which were infused with misinformation spread by anti-
vaccine propaganda [30]. The identification of particular
knowledge gaps supported the need to provide clear lay
language explanations that integrated with parents’
mental models in order to counter misinformation
about vaccination risks.
A mental models approach, however, is new to the con-
text of clinical trials. Mental models regarding experimen-
tal vaccines in clinical trials may share similarities with
those of licensed vaccines, for example, in regard to the
need for multiple injections; however, participating in
placebo-controlled trials is also quite distinct from uptake
of vaccines that have already been approved for public
licensure [27,31]. Identifying and understanding mental
models –individuals’ existing web of knowledge regarding
HIV vaccines and clinical trials– may support the develop-
ment of effective communication strategies to facilitate
community engagement and meaningful informed con-
sent, as well as recruitment and retention, in ethically
conducted clinical trials. With Phase II HIV vaccine trials
planned among MSM in India [9], we explored mental
models of candidate HIV vaccines and clinical trials.
Methods
The study protocol was approved by the Institutional
Review Boards of the University of Toronto and The
Humsafar Trust, Mumbai. All participants provided
written informed consent.
We used a community-based research approach [32];
community-based organizations (CBOs) serving MSM in
Chennai (Social Welfare Association for Men and
Sahodaran) and Mumbai (The Humsafar Trust) collabo-
rated throughout all stages of the research. We conducted
focus groups with MSM service users and MSM peer out-
reach educators from local CBOs in each city. Trained
peer outreach staff recruited focus group participants by
word of mouth, mitigating potential risks of printed
materials indicating MSM and HIV. We conducted key
informant (KI) interviews with MSM community leaders,
CBO staff and healthcare providers in each city.
Table 1 Sociodemographic characteristics of focus group
participants in Chennai and Mumbai, India (n = 68)
Characteristic n %
Age (years) Mean 28 –
Range 20-46 –
Marital status Unmarried 57 84
Married 11 16
Education Primary (<= 5th grade) 10 15
6th - 11th grade 22 32
High school degree 18 26
College degree 18 26
Employment Community agency staff 15 22
Daily wage labourer 16 24
Private company staff 19 28
Sex work 8 12
Unemployed 10 15
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self-identification as MSM, aged 18 years or above and
ability to provide informed consent. We used stratified
purposive sampling to include perspectives of different
MSM subgroups, with separate focus groups for kothis
(feminine gender expression and generally receptive
partners in anal sex), panthis (masculine gender expres-
sion and generally insertive partners in anal sex), and
double-deckers (both insertive and receptive roles). In
Chennai, CBO peer outreach educators had previously
taken part in community consultation meetings spon-
sored by the International AIDS Vaccine Initiative
(IAVI), which was exploring the feasibility of conducting
future HIV vaccine trials in India. We used purposive
sampling to select information-rich [33] key informants
with in depth knowledge of the study populations.
Data collection
We used a semi-structured interview guide to explore
knowledge and beliefs about HIV vaccines and clinical
trials. Focus groups (60–90 minutes) and interviews
(45–60 minutes) were conducted in participants’ native
language (Tamil in Chennai; Marathi or Hindi in Mumbai);
a few KIs chose to be interviewed in English. Focus
groups and interviews were audio-taped, transcribed
verbatim, redacted and translated into English. We
checked the accuracy of transcripts by randomly selecting
20% and comparing them with the respective audio files.
Data analysis
Focus group and interview data were explored using the-
matic analysis [34] and a constant comparative method
[35], with a focus on possible mental models of HIV
vaccines and clinical trials. We developed a code book
based on the interview guide and available literature and
added codes that emerged during analysis. Two bilingual
investigators individually analysed each transcript,
followed by team analysis using NVivo 7. Differences in
coding were resolved by consensus in research team
meetings. We sought to identify pre-existing mental
models and traced how they facilitated or hindered com-
prehension of basic scientific information regarding HIV
vaccine trials. Member checking was conducted by
discussing findings and interpretations in meetings with
field research teams and community leaders in each site
[36], with attention to differences in perspectives and in-
terpretations between key informant community leaders/
service providers and MSM CBO clients.
Results
Sociodemographic characteristics
We conducted seven focus groups (n = 43) in Chennai
and five (n = 25) in Mumbai. Participants’ mean age was
28 years. The majority (52%) of focus group participantsidentified as kothi, one-fifth (21%) as double-deckers
and about one-fifth (18%) panthis; 16% (n = 11) were
married. Notably, due to powerful sociocultural and
familial pressures in India, a substantial proportion of
self-identified MSM are married to women [3]. Most
participants were of lower socioeconomic status. Key
informants’ (n = 14) (mean age = 40 years) were MSM
CBO staff (n = 8) and leaders (n = 4), and healthcare
providers (n = 2) working with MSM, all with college
degrees. Additional sociodemographic characteristics
are reported in Table 1.
Vaccine-induced seropositivity (VISP) and fear of vaccine-
induced infection
A pervasive mental model was that testing HIV positive
as a response to a candidate vaccine signified actual
infection. Figure 1 depicts a mental model of VISP and
potential challenges as well as strategies to improve com-
prehension. Participants were largely unaware of VISP, ex-
cept for two peer educators who had been involved as
peer research interviewers in a formative research study
related to HIV vaccines. Testing “positive for HIV” was
equated with being infected (“there is HIV”), as partici-
pants were familiar with HIV antibody testing offered in
government voluntary HIV testing centres. The first time
the concept of VISP was explained by the facilitator, par-
ticipants did not comprehend it as testing positive for HIV
with no actual HIV infection. After additional explanation,
even those who eventually understood VISP had concerns
Pre-existing mental model 
Testing HIV-positive = HIV-infected  
“No one wants to have HIV” 
Alternative mental model 
“False-positive” HIV test result 
“One can test HIV-positive at the 
hospital/clinic, but not really be 
HIV-infected” 
Intervention strategy 
Educate MSM about VISP 
using ‘false-positive HIV 
antibody-based test’ as an 
example. Explain that 
fragments (natural or 
synthetic) of HIV cannot 
possibly cause HIV infection 
Assumption 1 
Fear of VISP  
“If a vaccine makes me 
test HIV-positive, it means 
I have HIV”  
Assumption 3 
Omission bias & anticipatory 
regret 
“I’ve worked hard to avoid HIV 
all my life by not having 
unprotected sex. If I contract 
HIV due to participating in a 
trial, it would be worse than 
getting HIV from not using a 
condom” 
Intervention strategy 
Explain and show potential 
volunteers PCR test 
examples that will be used 
to ‘prove’ that someone 
with VISP is not HIV-
infected 
New mental model 
Participating in an HIV Vaccine 
Trial May Cause HIV Infection 
“I will be placed at risk for HIV 
infection by the trial vaccine”
Challenge  
Even if MSM understand 
VISP, family members and 
the general public will not 
understand, which may lead 
to relationship problems with 
male and female partners; 
alienate family; and pose 
obstacles for overseas work 
visas
Intervention strategy 
Engage male and female 
partners in trial education 
sessions if participant desires; 
skill-building for trial volunteers to 
discuss VISP with significant 
others; availability of trial 
ombudsperson to intervene in 
difficult cases  
Assumption 2 
Anxiety about VISP 
“If I test HIV-positive, I will 
worry that I really have 
HIV…even if trial staff tell 
me I do not have HIV”  
Figure 1 Mental model of HIV vaccine-induced seropositivity among MSM in Chennai and Mumbai, India (n = 82).
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positive. Participants described situations in which trial
volunteers might be screened for HIV outside of a trial:
prevention-of-parent-to-child-transmission (PPTCT) pro-
grams in which the husband is encouraged to be tested
for HIV along with his wife; and pre-employment HIV
screening when applying for jobs abroad.
There are chances for MSM to go to PPTCT centre
during wife’s pregnancy; there are chances for both of
them to undergo HIV testing. At that time if he is
found to be ‘HIV positive’, what would happen?
(Kothi, FG2, Chennai)
Focus group facilitators gave brief explanations of can-
didate vaccines that may contain viral fragments or pos-
sibly inactivated (killed) whole viruses. One participantquestioned: “You said dead virus is put in. How do we
know? … After going in it drinks blood and becomes
alive, then?” (Kothi, FG6, Chennai).
The possibility of being infected by a candidate vaccine
led to trepidation among participants: “I am HIV-negative
and I have kept myself free of HIV for all these years…If I
become HIV-positive because of a [test] vaccine I’ll be
punished for a lifetime. I am scared about that” (Kothi,
FG1, Mumbai). Even with understanding of VISP, a partici-
pant explained the tremendous fear associated with HIV:
“One will definitely be shocked even if his result is false-
positive. Yes, a good and strong person may not be afraid of
anything but HIV. They are afraid of only one word –
‘HIV’. Do you get it?” (Double-decker, FG3, Chennai).
A kothi-identified peer educator similarly reported:
“We have explained about this [VISP], but whether
after knowing about VISP they [MSM community]
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everyone is afraid of testing positive for HIV” (KI4,
Chennai).
A participant expressed hope that “we can explain this
[VISP] to people,” as some MSM are already familiar
with the idea of “false-positive HIV tests”: “We can tell
them that similar to the possibilities of having a false-
positive HIV test result, even if one’s result comes as
HIV-positive, he is not really infected. We know they
won’t lament then, okay?” (Double-decker, FG3,
Chennai).
Another participant suggested using the media to
challenge mental models, and provided an example
from a well-known media campaign– “pulli rajavukku
AIDS varumaa” –roughly translated as, “Will a lucky
man [who is popular among women] get AIDS?” This
campaign in Tamil Nadu challenged the popular no-
tion that some persons will not get HIV even if they
engage in risky behaviours, because they are lucky.
If it is explained people will definitely understand.
Because people did not know much about HIV 7
or 10 years back, the advertisement “pulli
rajavukku AIDS varumaa” was frequently
broadcasted in the TV for a month’s period when
people could not immediately understand its
essence. Later on many got to know about the
concept since it was broadcasted in all TV
channels. So, similarly if you explain about the
vaccine trials they will come to know about it. So,
the message needs to tell the people that there are
chances for false-positive because of participating
in such research. This would really help them to
believe that they are negative even if they are
tested positive. (FG5, Chennai)Preventive misconception and behavioural disinhibition
A common mental model was that participation in
biomedical HIV prevention trials provides protection
against HIV infection. Figure 2 illustrates a mental
model of preventive misconception, the belief that one
gains protection by virtue of being enrolled in a preven-
tion trial [37]. This widespread belief was founded on
three fundamental misunderstandings: first, overestimation
of the likely effectiveness of a candidate vaccine; second,
lack of comprehension of “placebo” and randomization,
and overestimation of one’s chances of being assigned
to the experimental arm; and; third, that prevention tri-
als are intervention programs.
Participants specifically indicated belief in the efficacy
of candidate vaccines tested in clinical trials. A peer
educator explained that trial participants would think,
“If it [candidate vaccine] is not working, then whywould they [trialists] be actually testing it?” (KI6,
Chennai).
Peer outreach workers and a program director of an
HIV intervention project for MSM joked that once an
HIV vaccine is available for public use they will be un-
employed. Although intended in jest, this provides further
evidence of a mental model of HIV vaccines as nearly
100% effective; therefore there will be no further need for
condom education or distribution:
If there is no vaccine then there is no choice other
than condom; condom is a must. If vaccine is
available, condom use will become unimportant. One
will think “I have been vaccinated so I would not
require a condom.” (FG1, Chennai)
Another key informant provided a possible explan-
ation for belief in the efficacy of candidate vaccines in
clinical trials: “Usually one tends to believe that ‘some-
thing is better than nothing’. So, even if the volunteers
were informed that [trial] vaccine may or may not pro-
tect one from getting HIV, they would at least expect
some protection from it.” (KI2, Chennai).
Participants also explained that people will opt for easier
and less taxing ways to prevent HIV; accordingly, de-
creases in condom use among trial volunteers were seen
as “natural”, “normal”, “to be expected”, and even quite lo-
gical: “Now that one is on vaccine, condoms will be seen
as an additional burden. People usually think like that,
right?” (Kothi, FG2, Chennai).
Participants described the likelihood of widespread be-
havioural disinhibition due to preventive misconception
among trial volunteers resulting in less consistent con-
dom use for anal sex:
Kothis will not be careful in using condoms with panthis.
Once they are injected with vaccine, kothis will become
fully confident that they would never get infection. So
they will not insist their panthis to use condoms or they
would avoid using condoms. (Kothi, FG2, Chennai)When I get the vaccine I will feel that nothing
is going to happen to me. I can have sex with
whomever I want. (Kothi, FG1, Mumbai)Kothis [in sex work] would think “I won’t get
HIV because I have been given vaccine”. So they
will not use condoms in their sex work.
(KI3, Chennai)
The possibility that condom use among trial volunteers
may decrease posed a dilemma for community leaders
who manage HIV intervention programs. A community
leader in Chennai explained:
Assumption 5 
“It is natural for people not to 
adhere to a more demanding 
protective measure (e.g., 
condom use) when they feel 
protected by a relatively 
simpler measure (e.g., 
protection offered by the 
candidate vaccine)”
Assumption 1 
Overestimation of likely 
efficacy of candidate vaccine 
“Trialists would not be 
testing a vaccine if it were 
not very likely to be (100%) 
effective”  
Inference based on new 
mental model 
Behavioral Disinhibition
“Trial volunteers don’t 
need to use condoms as 
they are already protected” 
Assumption 2 
Overestimation of likelihood 
of being in the experimental 
group 
“I am very likely to get the 
candidate vaccine”
Intervention strategy 
Provide explicit information 
and education that most
products tested in clinical 
trials do not work 
Intervention strategy 
Provide explicit information 
that trial volunteers have 
equal chances of getting the 
test vaccine or the placebo; 
thus condom use is necessary 
Intervention strategy 
Provide explicit information 
that volunteers in a trial 
should use condoms; and 
that one is not asked to 
change one’s behavior to 
“help” the trial    
New mental model 
Preventive Misconception
“HIV vaccine trial volunteers 
gain protection against HIV 
infection”
Assumption 4 
“Trial volunteers should not 
use condoms as trialists 
then won’t know if the test 
vaccine works or not” 
Intervention strategy 
Ongoing counselling and 
testing with reminders that 
the trial vaccine is merely 
experimental and that one 
must continue to use 
condoms  
Assumption 3 
Vaccine trials are prevention 
programs 
“CBOs wouldn’t refer me to the 
trial if it were not going to protect 
me from HIV infection”  
Intervention strategy 
Provide explicit information that 
clinical trials (controlled medical 
experiments) are not the same as 
interventions; participation may not 
offer individual benefits, but may 
benefit the community/society 
Pre-existing mental model  
Vaccines protect 100% 
against infection 
Pre-existing mental model  
Prevention programs help 
to lower risk of HIV 
transmission 
Figure 2 Mental model of preventive misconception and behavioural disinhibition among MSM in Chennai and Mumbai, India (n = 82).
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develop a vaccine one needs people to participate.
But what if then people do not want to use
condoms? The work we have put in for several years
to promote condom use among MSM will then be
wasted. (KI1, Chennai)Placebo-controlled trials and random assignment
None of the focus group participants had heard of “pla-
cebo” before. Facilitators had difficulty in explaining
what a placebo is and why it is needed; the concept
was considered too technical to be explained in simple
terms and it was difficult to find suitable words orexamples in the vernacular of participants. Even after
the facilitator explained why a placebo and control
group were needed to conduct a clinical trial, participants
reported that most trial volunteers would not consistently
use condoms due to overestimating their likelihood of
being in the experimental vaccine group.
Participants reported the perception that double-blind
placebo-controlled trials amount to “cheating”. They
further reasoned that unblinding volunteers who re-
ceived placebo would make these volunteers less likely
to become careless and engage in sexual risk behaviours.
Therefore, it was seen as unethical on the part of trialists
not to disclose group assignment. This assertion suggests
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trial volunteers, and further presumes that most volun-
teers would overestimate experimental vaccine efficacy.
Peer educators and community leaders reported that if
even they, in spite of their long-term experience “in the
field of HIV”, found it difficult to understand the
concept of placebo, then MSM from the “grassroots
level” would definitely have difficulty in understanding it.
They reported that explaining double-blind assignment to
volunteers would pose problems for trial recruitment and
retention:
Community will not accept if we tell like this; even
people who accepted [to participate] earlier will now
not accept, because they would be afraid that they
are being cheated…they would not understand.
(Kothi, FG6, Chennai)[Trial participants] may not know much
information about placebo…They will believe that
“I have been given HIV vaccine, I can do whatever
I want…” (KI9, Chennai)
A key informant further indicated not understanding
how one can evaluate vaccine efficacy if everyone is
counselled to use condoms:
If you are not going to tell who is on placebo and who
is on HIV vaccine, then how would you know whether
vaccine is working or not as everyone is counselled to
use condoms? (KI1, Chennai)
Similarly, a key informant indicated suspicions that the
reason for blinding and a placebo was to deliberately mis-
lead volunteers that they are in the experimental vaccine
group so that they will not use condoms consistently,
which will then help in assessing vaccine efficacy.
Disclosure of STEP study outcomes to prospective trial
volunteers
Toward the end of the interview, facilitators and inter-
viewers provided brief information about the STEP study
in order to explore participants’ perspectives on what in-
formation should be shared with future trial volunteers.
Although this Phase IIb HIV vaccine trial with people at
high risk of HIV infection did not include India, the inter-
national multi-site trial was terminated early when it was
determined that the experimental vaccine would not prove
to be efficacious. Subsequently, it was shown that a sub-
group of trial volunteers who had received the experimen-
tal vaccine were placed at higher risk for HIV infection
than the placebo group [38,39]. In response to the STEP
study, broad changes have been implemented to better
ensure the safety of trial participants and experimentalvaccines to be tested; nevertheless, the unexpected harms
to volunteers in a clinical trial raised significant and
widely discussed challenges for HIV vaccine testing and
development.
Some MSM reported that trialists should disclose every-
thing about the STEP study so that MSM can decide for
themselves whether or not to participate. Not disclosing
STEP trial outcomes amounted to “cheating”:
We have to share it openly and only those who still
want to participate should then be referred; otherwise
it is wrong. (Kothi, FG6, Chennai)They should not lie because they think there would be
Beeli [problem] if they tell the details. Then it is like
misusing us; all information should be definitely
revealed. (KI1, Chennai)This information you should give so that later they
don’t blame [trialists] by saying, “Why didn’t you tell
us first?” (Panthi, FG5, Mumbai)
Alternately, some participants and community leaders
thought that because the STEP trial happened in other
countries and the same candidate vaccine is not going to
be tested in India (information provided by the facilita-
tor/interviewer), one need not disclose anything about
STEP. They further indicated that if this information
were provided then MSM would become afraid and not
want to participate at all: “People will be confused and
will not understand; so don’t tell”. (KI2, Chennai).
After hearing about the outcomes of the STEP study, a
key informant asserted that vaccine trials are conducted
in India because trialists see Indians as “guinea pigs”. He
described this as ‘neocolonialism,’ presuming that rich
countries largely benefit from the results of these trials:
Most of these trials are deliberately conducted
among people who are economically disadvantaged
and who are from developing countries…I even
doubt whether Phase I trial [in India] among
normal human volunteers was actually conducted.
(KI9, Chennai)
Doubt regarding the past implementation of a Phase I
trial (among healthy volunteers) in fact conducted in
India [9] was founded on the belief that no one from the
middle or upper classes would have volunteered for an
HIV vaccine trial.
A community leader similarly asked, “Whether trials
are happening in other countries?…Why this need to be
conducted among MSM in India, and not among FSWs
[female sex workers] or IDUs [injecting drug users]?” He
later expanded on this, saying that he posed these
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to the MSM communities he serves if they raise these
questions. If not, he added, clients of his agency would
think he had “sold” them to trial sponsors.
In contrast to key informants, focus group participants
rarely questioned the motivations behind the HIV vac-
cine trials planned with Indian MSM. One participant
indicated he was against such trials as he felt they would
only increase the negative image that the general public
has of MSM as a ‘high risk group’, and he also did not
want MSM to be treated as “experimental rats”.
Discussion
This study among Indian MSM revealed several common
mental models regarding HIV vaccine trials, some of
which indicated misunderstanding and misconceptions of
procedures fundamental to clinical research. With Phase
II trials planned among MSM in India in the near future,
understanding potential volunteers’ perspectives on candi-
date HIV vaccines and vaccine trials may yield insights to
support meaningful informed consent, recruitment and
retention, and the safe and ethical conduct of these trials.
A major concern emerged in relation to VISP, which
was perceived as a deterrent to otherwise willing MSM
volunteers participating in trials. The mental model that
an HIV-positive test result is the same as HIV-infection,
founded on familiarity with commonly used antibody-
based HIV tests in India, posed difficulties in understand-
ing that one can be HIV-positive but not HIV-infected.
Vaccine-induced infection, in addition to being feared in
its own right, also resulted in the anticipation of greater
regret than if one had contracted HIV due to unprotected
sex. This line of thinking is consistent with omission bias,
a frequently observed cognitive bias in decision-making
in which harms (i.e., HIV infection) due to acts of com-
mission (i.e., trial participation) tend to result in greater
regret than harms due to acts of omission (i.e., not using
a condom) [40,41].
Secondly, participants indicated concern about situa-
tions requiring HIV testing in that others (e.g., wives,
foreign employers, healthcare providers) may not accept
that they are not actually HIV infected. VISP was simi-
larly a primary barrier to HIV vaccine trial participation
among MSM who screened in as eligible but declined to
participate in a Phase IIb trial in North America; however,
the main concerns were about social consequences of
VISP rather than conflation of VISP with actual infection
[42]. Concerns about VISP may be exacerbated among
MSM in India due to pervasive sexual stigma and related
presumptions that all MSM are living with HIV (e.g.,
symbolic stigma) [43].
Participants also suggested strategies to impart under-
standing of VISP based on an alternate mental model de-
rived from false-positive HIV tests, a concept with whichmany MSM are familiar (see Figure 1). This suggests that
the pre-existing web of knowledge that may fuel misun-
derstanding may be marshalled to correct misperceptions
about a particular concept (such as VISP), accurate under-
standing of which in turn may influence trial participation.
Importantly, this also suggests that possible strategies to
engage with mental models in order to correct mispercep-
tions may emerge from communities themselves.
Although fear of vaccine-induced infection has been
documented in studies of individuals who screened in
but declined to participate in an HIV vaccine trial [27]
and most-at-risk populations for HIV infection [44], it did
not emerge as a major issue in focus group discussions. A
few participants indicated apprehensions that live virus
might emerge from inactivated virus vaccines and infect
people. Rather, participants’ concerns were primarily fo-
cused on how to detect actual infection in a trial volunteer
whose HIV-positive antibody test result might be mistaken
as VISP. These concerns may be addressed by trialists
through educational interventions for potential trial volun-
teers and by ensuring free access to viral nucleic acid-
based diagnostic tests, such as polymerase chain reaction
(PCR) tests [42,45].
Of particular concern, preventive misconception was
widely in evidence among study participants, supported
by a mental model of prevention trials as synonymous
with preventive interventions (Figure 2). Some partici-
pants reasoned that MSM advocates from CBOs wouldn’t
refer them to a trial if there weren’t some personal benefit
for participants. Participants reported that as a result,
MSM trial volunteers would exhibit behavioural disin-
hibition through less consistent use of condoms. We
identified overestimation of the likelihood of a candidate
vaccine being effective in offering personal protection—a
belief in the efficacy of candidate vaccines—based on a
mental model of vaccines as 100% effective as well as over-
estimation of assignment to the experimental group.
Several different rationales were revealed in support of
these beliefs: 1) Vaccines, in general, were believed to
provide complete protection against infection; there-
fore, candidate HIV vaccines were seen as likely to pro-
tect trial volunteers from HIV infection; 2) Participants
reasoned that trialists would not be spending time and
resources on testing a product that is not very likely to
be effective; 3) Some participants articulated that trusted
CBOs, with longstanding records of providing referrals to
competent health and social services, would not refer
clients to participate in clinical trials if the products to be
tested were not going to be effective; and, 4) The view that
“something is better than nothing”; so by merely partici-
pating in the trial, one is necessarily safer than in not
participating.
Participants also demonstrated widespread lack of
understanding of “placebo” as well as the rationale for a
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interviewer, several participants and key informants still in-
dicated overestimation of the likelihood of being assigned
to the experimental group, which supported preventive
misconception. Thus, mental models of prevention trials as
interventions and vaccines as completely efficacious, along
with lack of understanding of placebo and random assign-
ment, were reported as likely to lead to widespread behav-
ioural disinhibition among MSM trial volunteers.
Preventive misconception constitutes what may be
an inappropriate motivation for participating in a clinical
trial based on lack of comprehension of the trial’s purpose
or a sense of invincibility [44,46,47]. Importantly, this mis-
conception may enable behavioural disinhibition, resulting
in increased risk to participants [37,47,48]. The mental
model of preventive misconception (Figure 2) suggests
that intervention strategies to challenge misconceptions
about experimental vaccine efficacy and randomization,
and thereby to mitigate the potential for increased risk
behaviours (e.g., not using a condom) based on those
beliefs, should include provision of explicit and consist-
ently reinforced information and education to the effect
that: 1) clinical trials are not the same as interventions;
2) most products tested in clinical trials do not work;
and, 3) trial volunteers have equal chances of getting the
test vaccine or the placebo.
The particular sociocultural context of kothis in India
also may impact on behavioural disinhibition: the per-
ceived opportunity to forego condom use may be ex-
perienced as consonant with kothis’ feminine gender
expression and desire to attract panthis, in addition to
being incentivized by saving on the cost of condoms and
averting logistical challenges of negotiating condom use.
Interestingly, participants invoked a former Indian AIDS
education media campaign—which used a macho char-
acter to challenge the notion that one avoids HIV by be-
ing “lucky” rather than by using condoms—as a possible
model for mitigating preventive misconception. The spe-
cific beliefs that contribute to preventive misconception
could be integrated into such a campaign as targets for
change.
Another mental model that emerged across partici-
pants was the belief that it is wrong to conceal some-
thing that might harm someone, with a strong value placed
on transparency. This led to criticisms of the very basis for
randomised controlled trials (RCTs), in the use of placebo-
controls and double-blinding, and further influenced opin-
ions on the importance of providing information about the
outcomes of the STEP study to all potential HIV vaccine
trial volunteers.
An additional permutation on the theme of transpar-
ency was invoked by key informants, who suspected that
the reason for implementation of HIV vaccine trials in
India is that foreign institutions want to benefit by usinglow socioeconomic, marginalised Indian populations as
‘guinea pigs’. In fact, conducting clinical trials in India re-
quires technical and ethical clearance from the govern-
ment, with approval by the Indian Council of Medical
Research (ICMR). However, the perception among key in-
formants, who had higher education and occupied leader-
ship roles, that vulnerable Indian people were being used
as guinea pigs may be founded on injustices and economic
motivations reminiscent of the colonial era and perceived
Indian governmental indifference to marginalised commu-
nities [9]. The disenfranchisement of MSM from main-
stream Indian society may make issues of mistrust more
salient in their mental models of HIV vaccine trials.
Mistrust regarding clinical trials raises the importance
of explicitly addressing doubts in the minds of both
MSM community leaders and grassroots level MSM
about the motivations behind HIV vaccine trials and
who is sponsoring the trial, along with demonstrating
how the trial may benefit Indian MSM and other
marginalised communities. Distrust of foreign sponsors,
in particular, supports the value of having policies and
funding mechanisms in place to enable access in low-
and middle-income countries, particularly among trial
volunteers, to HIV vaccines that demonstrate efficacy in
clinical trials, once approved and licensed [6].
Further challenges remain in how to inculcate research
literacy, including basic comprehension of concepts such
as placebo, randomization and the scientific rationale for
RCTs, as well as how to share information about possible
risks due to unpredictable negative consequences (like
those in the STEP study) without unnecessarily scaring
potential participants. A strategy informed by mental
models might use the analogy of side effects of licensed
medications, for example, to help explain unpredictable
adverse effects of experimental vaccines. In the Indian
context, building on a commonly used expression in
Tamil, which can be translated as “effective medicine will
taste bitter”, also might help to communicate risks of
potential side effects to low socioeconomic status MSM.
Key informants largely corroborated the perspectives
of focus group participants drawn from the clientele of
MSM CBOs, including concerns about VISP, preventive
misconception and difficulty in understanding the need
for random assignment and placebo. Notably, ideas for
possible solutions for resolving misunderstandings (e.g.,
in relation to VISP) emerged from both key informants
and MSM clients. Different perspectives were revealed
in key informants being more likely to insist on the im-
portance of disclosing and explaining the STEP study
outcomes to future trial volunteers—a position aligned
with the ethical basis of informed consent [49]—and more
likely to question the motivations of outsiders (e.g.,
multinational corporations and foreign governments)
in conducting trials among Indian MSM.
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As a qualitative study using purposive sampling, our
findings may not apply across MSM populations in
India; our intention was to understand in-depth rather
than to generalise. In particular, the study sample
may be more representative of lower socioeconomic
MSM with kothi, panthi and double-decker identities
who use CBO services; middle- and upper-class MSM,
particularly those who have gay or bisexual identities,
and MSM who do not access CBO services, may
have different mental models of concepts related to
HIV vaccines and clinical trials. Further research also
may help to determine potential differences in men-
tal models of HIV vaccines and clinical trials across
different subgroups of MSM. An additional limita-
tion is that participant responses may differ in re-
sponse to an actual HIV vaccine trial; however our
purpose was to anticipate challenges to comprehen-
sion and potential risks in advance of trial implementation.
Implications for practice and research
The evidence of broadly shared mental models related
to HIV vaccines and clinical trials suggests a mental
models approach may be used to support and augment
efforts to inculcate scientific literacy in order to promote
the ethical conduct of future HIV vaccine trials in India.
Mental models may be used to impart new information
that is integrated with pre-existing knowledge, as in the
case of explaining VISP based on comprehension of
false-positive HIV tests. Accurate assessment of the
bases for potential ethical challenges in clinical research
is important to effectively mitigate risks and to support
meaningful informed consent [46].
Nevertheless, mental models should be mobilised
with reasonable caution, as indicated by a case study
from South Africa: well-meaning foreign researchers
may have mistakenly promoted folk beliefs among
local communities about witchcraft as the source of
HIV, thereby fuelling HIV stigma and even violence, in
using what appeared to be an apt analogy of a snake
to explain how antiretroviral medications work [50].
However, the conclusion offered in the case study
that suggests one must choose either to inculcate sci-
entific literacy or to adopt a mental models approach
appears to be oversimplified. The present study sug-
gests that efforts to promote scientific literacy alone
may not be sufficient to confer understanding and ac-
ceptance of the rationale for placebos, control groups
and randomization in clinical trials, nor to disavow
participants and local communities of preventive mis-
conception, or to mitigate the impact of mistrust
founded on a history of colonial era abuses of medical
research. A mental models approach may reveal par-
ticular misconceptions and the underlying architectureof beliefs to help guide the focus and content of scien-
tific literacy efforts and to augment those efforts in
order to improve comprehension and acceptance of
the legitimacy of scientific concepts.
Importantly, the basis for preventive misconception in
the present study seems to be broader than that indicated
in previous empirical research conducted in the U.S. [37].
In addition to overestimating the likely personal effective-
ness of an experimental vaccine and overestimating one’s
chances of assignment to the experimental arm, we identi-
fied pervasive misunderstanding and lack of acceptance of
placebo and random assignment, imputations that trialists
and CBO referral sources alike must think the product will
work as otherwise they would not be expending consider-
able resources and encouraging potential participants to
volunteer, and a general belief that HIV prevention trials
are intervention programs.
The present study suggests that engaging in discussion
of the potential benefits and risks of clinical trials from
the perspectives and belief systems of local communities,
supporting policies and funding mechanisms that ensure
access among trial volunteers to products that demon-
strate efficacy in trials, as well as inculcating scientific lit-
eracy may help to advance the highest ethical standards in
conducting research among MSM in India. Possible socio-
cultural differences in belief systems and the bases for trial
misconceptions by population and geography suggest the
importance of conducting formative research in situ
before launching clinical trials, and the usefulness of a
mental models approach.
Finally, although present-day trials in India are subject
to government approval and ethical and safety standards,
the present data suggest the importance of engaging
with mental models of medical research that may be
based on colonialist histories with clinical trial participants
seen as “guinea pigs” or “experimental rats”, rather than
merely attempting to controvert these beliefs through
science. Interestingly these beliefs tended to arise more
among the most educated among the sample, some of
whom are advocates and service providers who viewed
themselves as protecting marginalised communities, ra-
ther than among MSM clients themselves. Nevertheless,
these key informants may be a highly important constitu-
ency to ensure effective community engagement through
civil society representatives, which may be a key element
in the successful implementation of biomedical HIV
prevention trials [51,52].
Conclusion
This qualitative investigation elicited mental models
among MSM in India that may raise challenges for
recruitment efforts and the ethical implementation of
HIV vaccine trials. By understanding and mapping the
existing web of knowledge in regard to HIV vaccines
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support as well as challenge misinterpretations, we may
develop evidence informed communication strategies to
impart accurate, comprehensible and acceptable infor-
mation to marginalised communities, such as MSM, in
which biomedical HIV prevention trials are planned.
Abbreviations
MSM: Men who have sex with men; CBO: Community-based organization;
KI: Key informant; IAVI: International AIDS Vaccine Initiative; VISP: Vaccine-induced
seropositivity; PPTCT: Prevention-of-parent-to-child-transmission; FSW: Female sex
worker; IDU: Injecting drug user; PCR: Polymerase chain reaction;
RCT: Randomised controlled trial; ICMR: Indian Council of Medical Research.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VC designed the study, supervised data collection and analysis, and drafted
the manuscript. PAN designed the study, consulted on data collection and
analysis, and wrote the final manuscript. NS implemented and supervised
data collection in Mumbai and contributed to data analysis and drafting the
results. RN implemented and supervised data collection in Chennai and
assisted in interpretation of the results. MS coordinated data collection and
contributed to data analysis and interpretation of the results. All authors read
and approved the final manuscript.
Acknowledgements
We gratefully acknowledge our community collaborators, The Humsafar
Trust, Social Welfare Association for Men (SWAM) and Sahodaran, community
outreach workers and interviewers for critical contributions to the research.
We thank all participants and key informants for sharing their perspectives.
We also wish to thank Suchon Tepjan for assistance in preparing the
manuscript and Vivek Anand, Joanne Daciuk and Lily Wong for
administrative support. This research was supported by grants from the
Canadian Institutes of Health Research (MOP-102512; THA-118570), the
Canada Research Chairs program and the Canada Foundation for Innovation.
Author details
1Centre for Sexuality and Health Research and Policy (C-SHaRP), 38 (Old No.
167), Ground Floor, Rangarajapuram Main Road, Kodambakkam, Chennai
600024 India. 2Factor-Inwentash Faculty of Social Work, University of Toronto,
246 Bloor Street West, Toronto, Ontario M5S 1V4 Canada. 3The Humsafar
Trust, III floor, Manthan Plaza, Nehru Road, Vakola, Santacruz (East), Mumbai
400 055 India.
Received: 4 March 2013 Accepted: 1 August 2013
Published: 7 August 2013
References
1. Lidz CW, Appelbaum PS, Grisso T, Renaud M: Therapeutic misconception and
the appreciation of risks in clinical trials. Soc Sci Med 1982, 58:1689–1697.
2. Lindegger G, Richter LM: HIV vaccine trials: critical issues in informed
consent. S Afr J Sci 2000, 96:313–317.
3. Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M:
Willingness to participate in HIV vaccine trials among men who have sex
with men in Chennai and Mumbai, India: a social ecological approach.
PLoS One 2012, 7(12):e51080.
4. Lindegger G, Milford C, Slack C, Quayle M, Xaba X, Vardas E: Beyond the
checklist: assessing understanding for HIV vaccine trial participation in
South Africa. J Acquir Immune Defic Syndr 2007, 43(5):560–566.
5. Excler JL, Beyrer C: Human immunodeficiency virus vaccine development in
developing countries: are efficacy trials feasible? J Hum Virol 2000, 3:193–214.
6. Guenter D, Esparza J, Macklin R: Ethical considerations in international HIV
vaccine trials: summary of a consultative process conducted by the Joint
United Nations Programme on HIV/AIDS (UNAIDS). J Med Ethics 2000,
26:37–43.
7. Lurie P, Bishaw M, Chesney MA, Cooke M, Fernandes ME, Hearst N,
Katongole-Mbidde E, Koetsawang S, Lindan CP, Mandel J, Mhloyi M, CoatesTJ: Ethical, behavioral, and social aspects of HIV vaccine trials in
developing countries. JAMA 1994, 271(4):295–301.
8. UNAIDS: Global Report: UNAIDS Report on the Global AIDS Epidemic 2010.
Geneva; 2010. http://www.unaids.org/globalreport/global_report.htm.
9. Excler JL, Kochhar S, Kapoor S, Das S, Bahri J, Ghosh MD, Ganguly NK,
Nayyar A, Chataway M: Preparedness for AIDS vaccine trials in India.
Indian J Med Res 2008, 127(6):531–538.
10. Sharma DC: Research halted at Indian centre accused of misconduct.
Lancet 2001, 358(9286):992.
11. Thorat MA: Medical research in India. Lancet 2006, 368(9536):643–644.
12. Jesani A, Coutinho L: AIDS vaccine trials in India: ethical benchmarks and
unanswered questions. Indian J Med Ethics 2007, 4:2–3.
13. Nayyar A: AIDS vaccine trials for India: getting the facts right. Indian J
Med Ethics 2007, 4:109–110.
14. Padma TV: India stops further trials of HIV vaccine. In Science and
Development Network. 2007. http://webcache.googleusercontent.com/search?
q=cache:bXNeT7BygfQJ:www.scidev.net/fr/news/l-inde-met-un-terme-aux-es
sais-d-un-vaccin-contre-.html%3Fscimob%3D1+&cd=1&hl=en&ct=clnk&gl=th.
15. Chaturvedi S, Dasgupta R, Adhish V, Ganguly KK, Rai S, Sushant L, Srabasti S,
Arora NK: Deconstructing social resistance to pulse polio campaign in
two North Indian districts. Indian Pediatr 2009, 46(11):963–974.
16. Hussain RS, McGarvey ST, Shahab T, Fruzzetti LM: Fatigue and fear with
shifting polio eradication strategies in India: a study of social resistance
to vaccination. PLoS One 2012, 7(9):e46274.
17. Mattheij I, Pollock AM, Brhlikova P: Do cervical cancer data justify HPV
vaccination in India? Epidemiological data sources and comprehensiveness.
J R Soc Med 2012, 105(6):250–262.
18. Suba EJ, Raab SS: HPV vaccination: waiting for evidence of effectiveness.
Lancet 2010, 375(9715):639–640.
19. Mudur G: Row erupts over study of HPV vaccine in 23,000 girls in India.
BMJ 2012, 345:e4390.
20. Pandey V: Cancer vaccine programme suspended after 4 girls die. [http://www.
dnaindia.com/india/report_cancer-vaccine-programme-suspended-after-4-girls-
die_1368681]
21. Dhar A: Centre halts HPV vaccine project. [http://www.hindu.com/2010/04/
08/stories/2010040857390100.htm]
22. Ray SG, Majumdar K: The cervical cancer bazaar. Tehelka Magazine 2010, 7(11).
http://archive.tehelka.com/story_main44.asp?filename=Ne200310coverstory.asp.
23. Misra G: Decriminalising homosexuality in India. Reprod Health Matters
2009, 17(34):20–28.
24. Thomas B, Mimiaga MJ, Kumar S, Swaminathan S, Safren SA, Mayer KH: HIV
in Indian MSM: reasons for a concentrated epidemic & strategies for
prevention. Indian J Med Res 2011, 134(6):920–929.
25. Johnson-Laird PN: Mental models and human reasoning. Proc Natl Acad
Sci 2010, 107(43):18243–18250.
26. Morgan MG, Fischhoff B, Bostrom A, Atman CJ: Risk Communication: A
Mental Models Approach. New York: Cambridge University Press; 2002.
27. Newman PA, Seiden DS, Roberts KJ, Kakinami L, Duan N: A small dose of HIV?
HIV vaccine mental models and risk communication. Health Educ Behav
2009, 36(2):321–333.
28. Lynam T, Brown K: Mental models in human-environment interactions:
theory, policy implications, and methodological explorations. Ecol Soc 2011,
17(3):24.
29. Bostrom A: Vaccine risk communication: lessons from risk perception,
decision-making and environmental risk communication. Risk Health Saf
Environ 1997, 8:173–200.
30. Downs JS, Bruine de Bruin W, Fischhoff W: Parents’ vaccination
comprehension and decisions. Vaccine 2008, 26:1595–1607.
31. Newman PA, Yim S, Daley A, Walisser R, Halpenny R, Cunningham W, Loutfy
M: “Once bitten, twice shy”: participant perspectives in the aftermath of
an early HIV vaccine trial termination. Vaccine 2011, 29(3):451–458.
32. Horowitz CR, Robinson M, Seifer S: Community-based participatory
research from the margin to the mainstream: are researchers prepared?
Circulation 2009, 119(19):2633–2642.
33. Patton MQ: Qualitative Research and Evaluation Methods. Thousand Oaks:
Sage Publications; 2002.
34. Guest G, MacQueen KM, Namey EE: Applied Thematic Analysis. Thousand
Oaks: Sage Publications; 2012.
35. Charmaz K: Constructing Grounded Theory: A Practical Guide Through
Qualitative Analysis. Thousand Oaks: Sage Publications; 2006.
36. Lincoln YS, Guba EG: Naturalistic Inquiry. Newbury Park: Sage Publications; 1985.
Chakrapani et al. BMC Public Health 2013, 13:731 Page 12 of 12
http://www.biomedcentral.com/1471-2458/13/73137. Simon AE, Wu AW, Lavori PW, Sugarman J: Preventive misconception: its
nature, presence, and ethical implications for research. Am J Prev Med
2007, 32(5):370–374.
38. Sekaly RP: The failed HIV Merck vaccine study: a step back or a launching
point for future vaccine development? J Exp Med 2008, 205(1):7–12.
39. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert
PB, Lama JR, Marmor M, del Rio C, McElrath MJ, Casimiro DR, Gottesdiener
KM, Chodakewitz JA, Corey L, Robertson MN, the Step Study Protocol Team:
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step
Study): a double-blind, randomised, placebo-controlled, test-of-concept
trial. Lancet 2008, 372:1881–1893.
40. Kahneman D, Miller DT: Norm theory: comparing reality to its alternatives.
Psychol Rev 1986, 93:136–153.
41. Kahneman D, Tversky A: Choices, values, and frames. Am Psychol 1984,
39:341–350.
42. Newman PA, Daley A, Halpenny R, Loutfy M: Community heroes or ‘high-
risk’ pariahs? Reasons for declining to enroll in an HIV vaccine trial.
Vaccine 2008, 26(8):1091–1097.
43. Logie CH, Newman PA, Chakrapani V, Shunmugam M: Adapting the
minority stress model: associations between gender non-conformity
stigma, HIV-related stigma and depression among men who have sex
with men in South India. Soc Sci Med 2012, 74(8):1261–1268.
44. Newman PA, Logie C, James L, Charles T, Maxwell J, Salam K, Woodford M:
‘Speaking the dialect’: understanding public discourse in the aftermath of
an HIV vaccine trial shutdown. Am J Public Health 2011, 101(9):1749–1758.
45. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E:
Determinants of enrollment in a preventive HIV vaccine trial:
hypothetical versus actual willingness and barriers to participation.
J Acquir Immune Defic Syndr 2004, 36(1):604–612.
46. Emanuel EJ, Currie XE, Herman A: Undue inducement in clinical research
in developing countries: is it a worry? Lancet 2005, 366:336–340.
47. Woodsong C, Alleman P, Musara P, Chandipwisa A, Chirenje M, Martinson F,
Hoffman I: Preventive misconception as a motivation for participation and
adherence in microbicide trials: evidence from female participants and
male partners in Malawi and Zimbabwe. AIDS Behav 2012, 16(3):785–790.
48. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M,
Novak RM, Mayer K, Creticos C, Orozco-Cronin P, Popovic V, Mastro TD,
VISION/VAX004 Study Team: HIV sexual risk behavior over 36 months of
follow-up in the world’s first HIV vaccine efficacy trial. J Acquir Immune
Defic Syndr 2005, 39:90–101.
49. Flory J, Emanuel EJ: Interventions to improve research participants’
understanding in informed consent for research: a systematic review.
JAMA 2004, 292:1593–1601.
50. Ashforth A, Nattrass N: Ambiguities of ‘culture’ and the antiretroviral
rollout in South Africa. Soc Dyn 2005, 31(2):285–303.
51. Koen J, Essack Z, Slack C, Lindegger G, Newman PA: ‘It looks like you just
want them when things get rough’: civil society perspectives on negative
trial results and stakeholder engagement in HIV prevention trials. Dev World
Bioeth: . Epub ahead of print. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-
8847.2012.00338.x/abstract.
52. Newman PA: Towards a science of community engagement. Lancet 2006,
367(9507):302.
doi:10.1186/1471-2458-13-731
Cite this article as: Chakrapani et al.: “If It’s Not Working, Why Would
They Be Testing It?”: mental models of HIV vaccine trials and preventive
misconception among men who have sex with men in India. BMC Public
Health 2013 13:731.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
